Rapid Novor Inc

Some binders never get a second chance.

Early antibody selection decisions determine which candidates move forward and which are left behind, but not all screening methods give you all the information you need to make the best decision moving forward.

Our SPR Kinetic Screening using the Biacore 1K is designed to uncover the interactions that less sensitive approaches can miss.

Because the best hit might have been the one that was left behind.

From discovery to validation: what's possible when antibody discovery, SPR, and HDX-MS experts work together?

In our upcoming webinar, see how a protein-first workflow enabled the discovery of anti-idiotype antibodies with distinct epitope signatures, diverse affinity profiles, and a range of functional behaviors.

📅 𝗗𝗮𝘁𝗲: June 23, 2026 | 10:00 AM EST
🔗 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗻𝗼𝘄: https://hubs.li/Q04l3Y0q0

𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗧𝗲𝗮𝗺:
• Thierry Le Bihan, PhD: 𝘝𝘗 𝘙&𝘋, 𝘗𝘰𝘭𝘺𝘤𝘭𝘰𝘯𝘢𝘭 𝘈𝘯𝘵𝘪𝘣𝘰𝘥𝘺 𝘚𝘦𝘲𝘶𝘦𝘯𝘤𝘪𝘯𝘨
• Marko Jovic, PhD: 𝘗𝘳𝘰𝘥𝘶𝘤𝘵 𝘮𝘢𝘯𝘢𝘨𝘦𝘳, 𝘚𝘗𝘙
• Dominic Narang, PhD: 𝘔𝘢𝘯𝘢𝘨𝘦𝘳, 𝘏𝘋𝘟-𝘔𝘚 𝘚𝘦𝘳𝘷𝘪𝘤𝘦𝘴

Webinar: Anti-Idiotype Antibody Discovery and Characterization with SPR and HDX-MS In this webinar, you will learn: How integrated protein sequencing, SPR, and HDX-MS workflows can accelerate anti-idiotype antibody discovery pipelines. Strategies to discover all three functional anti-idiotype antibody subtypes with strong functional performance and low cross-reactivity to endogeno...

It’s not too late to get all of your hits 🎯

Our new SPR Kinetic Screening service on Biacore 1K is designed to help researchers identify, validate, and rank candidates with greater confidence, while detecting interactions that can be overlooked by less sensitive screening approaches.

𝗪𝗵𝗲𝗻 𝗲𝗮𝗿𝗹𝘆 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀 𝗺𝗮𝘁𝘁𝗲𝗿, 𝘀𝘁𝗮𝗿𝘁 𝘄𝗶𝘁𝗵 𝗸𝗶𝗻𝗲𝘁𝗶𝗰 𝗱𝗮𝘁𝗮 𝘆𝗼𝘂 𝗰𝗮𝗻 𝘁𝗿𝘂𝘀𝘁.

𝗖𝗮𝗻 𝗮 𝘀𝘁𝗿𝗲𝗮𝗺𝗹𝗶𝗻𝗲𝗱 𝗮𝗻𝘁𝗶-𝗶𝗱𝗶𝗼𝘁𝘆𝗽𝗲 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝘄𝗼𝗿𝗸𝗳𝗹𝗼𝘄 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗲 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 𝘁𝗵𝗮𝘁 𝗿𝗶𝘃𝗮𝗹, 𝗼𝗿 𝗲𝘃𝗲𝗻 𝗼𝘂𝘁𝗽𝗲𝗿𝗳𝗼𝗿𝗺 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗿𝗲𝗮𝗴𝗲𝗻𝘁𝘀?

Join us for a live webinar on June 23, where we'll explore how our integrated protein sequencing and characterization workflow can accelerate anti-idiotype discovery while generating antibodies with unmatched performance metrics.

🧪 𝗪𝗲𝗯𝗶𝗻𝗮𝗿: Unbeatable Anti-Idiotype Antibodies: Direct Discovery with Protein Sequencing, SPR, and HDX-MS
📅 𝗗𝗮𝘁𝗲: Tuesday, June 23, 2026
🕚 𝗧𝗶𝗺𝗲: 10:00 AM EST

👇 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗻𝗼𝘄 𝘁𝗼 𝘀𝗮𝘃𝗲 𝘆𝗼𝘂𝗿 𝘀𝗽𝗼𝘁!
https://hubs.li/Q04jWVfz0

Webinar: Anti-Idiotype Antibody Discovery and Characterization with SPR and HDX-MS In this webinar, you will learn: How integrated protein sequencing, SPR, and HDX-MS workflows can accelerate anti-idiotype antibody discovery pipelines. Strategies to discover all three functional anti-idiotype antibody subtypes with strong functional performance and low cross-reactivity to endogeno...

Heading to ASMS 2026? Check out our poster with the latest HDX-MS data for our anti-idiotype antibody discovery workflow!

📌 Poster presented by Dominic Narang
📅 June 2, 2026
🧪Antibodies & Antibody Drug Conjugates I

Understanding why certain viral mutations become evolutionarily advantageous requires more than static protein structures; it requires studying proteins in motion, in environments that closely resemble their native biological context.

For SARS-CoV-2, much of what we know about the spike protein structure comes from engineered soluble constructs designed for biochemical and structural studies or for vaccines. A recent study by Sophie Shoemaker and colleagues at UC Berkeley and the Gladstone Institute of Virology addresses this gap by combining HDX-MS with enveloped virus-like particles (eVLPs) displaying full-length spike protein in a near-native membrane environment.

💡 𝗞𝗲𝘆 𝗙𝗶𝗻𝗱𝗶𝗻𝗴𝘀 💡
• 𝗩𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝘁𝗵𝗲 𝗼𝗽𝗲𝗻-𝗶𝗻𝘁𝗲𝗿𝗳𝗮𝗰𝗲 𝘁𝗿𝗶𝗺𝗲𝗿 𝗶𝗻 𝗮 𝗻𝗮𝘁𝗶𝘃𝗲 𝗺𝗲𝗺𝗯𝗿𝗮𝗻𝗲 𝗲𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁: The open-interface trimer was confirmed in membrane-embedded spike, showing that this conformation is an inherent property of the protein rather than an artifact of engineered soluble constructs.
• 𝗧𝗵𝗲 𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗮𝗿𝘆 𝗮𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗺𝘂𝗹𝘁𝗶𝗯𝗮𝘀𝗶𝗰 𝗳𝘂𝗿𝗶𝗻 𝗰𝗹𝗲𝗮𝘃𝗮𝗴𝗲 𝘀𝗶𝘁𝗲: The additional basic residue in SARS-CoV-2 enhances furin cleavage efficiency. Cleavage at S1/S2 allosterically increases flexibility at the S2′ site, promoting TMPRSS2 processing and membrane fusion, but also favors formation of the open-interface trimer.
• 𝗧𝗵𝗲 𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗮𝗿𝘆 𝗮𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗗𝟲𝟭𝟰𝗚 𝗺𝘂𝘁𝗮𝘁𝗶𝗼𝗻: D614G stabilizes the closed prefusion trimer, counteracting furin-driven destabilization and reducing premature S1 shedding that could render the virus noninfectious.

HDX-MS is uniquely suited to studies like this because it captures conformational dynamics at peptide resolution without disrupting the native complex. By enabling researchers to probe flexibility, allostery, and transient conformational states, HDX-MS provides insights that static structural techniques alone often cannot capture.

📄𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝘀𝘁𝘂𝗱𝘆 𝗵𝗲𝗿𝗲: https://hubs.li/Q04hw9Vn0

🔬𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗮𝗯𝗼𝘂𝘁 𝗛𝗗𝗫-𝗠𝗦 𝗵𝗲𝗿𝗲: https://hubs.li/Q04hwbDg0

🎬We’re live from PEGs Boston!

Jennifer Crha, Kyle Annibale, Mingjie Xie, Thierry Le Bihan, (and mAbel the moose 🫎) are here all week to dive into de novo polyclonal antibody sequencing, epitope mapping, and antibody characterization.

You can find us at ⬇️
📍 𝗕𝗼𝗼𝘁𝗵 #𝟯𝟭𝟴
📌 𝗣𝗼𝘀𝘁𝗲𝗿 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻: Thursday, May 15 | "Conversion of Polyclonal Anti-Idiotypes into Characterized Recombinant Antibodies"

One of the highlights so far? Welcoming a very special guest: Jennifer's mom, and a longtime Rapid Novor supporter. 😊

If you’re attending PEGS this week, come say hello!

Technology has come a long way, but some things never change… 😅

What's one thing that would improve your life in the lab?

We’re counting down to and excited to be part of this year’s event!

📍Stop by Booth 318 anytime next week (May 11–15) to connect with Mingjie Xie, Thierry le Bihan, Jennifer Crha, and Kyle Annibale.

Catch Thierry’s presentation on anti-idiotype antibodies on Tuesday and the corresponding poster on Thursday!

𝘊𝘰𝘯𝘷𝘦𝘳𝘴𝘪𝘰𝘯 𝘰𝘧 𝘗𝘰𝘭𝘺𝘤𝘭𝘰𝘯𝘢𝘭 𝘈𝘯𝘵𝘪-𝘐𝘥𝘪𝘰𝘵𝘺𝘱𝘦𝘴 𝘪𝘯𝘵𝘰 𝘊𝘩𝘢𝘳𝘢𝘤𝘵𝘦𝘳𝘪𝘻𝘦𝘥 𝘙𝘦𝘤𝘰𝘮𝘣𝘪𝘯𝘢𝘯𝘵 𝘈𝘯𝘵𝘪𝘣𝘰𝘥𝘪𝘦𝘴:

💬𝗣𝗼𝗱𝗶𝘂𝗺 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 - Track C2A
Tuesday May 12, 12:15 PM

📊 𝗣𝗼𝘀𝘁𝗲𝗿 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 – Poster C091
Thursday May 15 (all day)

We’re looking forward to sharing how our REpAb platform is advancing polyclonal antibody discovery—enabling the conversion of complex mixtures into well-defined recombinant reagents.

See you there!

🥳 We just celebrated our 11th anniversary!

Only five months in, and this year is already one for the books. EasyM received a provisional licence from the Ontario Ministry of Health (MOH) to provide testing for Canadian patients, and we completed enrollment for the first Canadian prospective clinical study evaluating EasyM; huge wins for our team and for patients across Canada.

We celebrated the only way we know how: with good food and good company (don't worry, we made sure our remote teammates felt included too 😉)

Here's to 11 years of great science and even greater people. Thank you to everyone who has been part of this journey!